Fulgent Genetics reported second quarter 2026 revenue of $85.4 million and a GAAP net loss of $29.5 million ($1.05 per share). The company revised its full-year 2026 revenue guidance downward to $330.0-$340.0 million due to processing delays impacting collection rates during the final phase of a billing system transition. Fulgent purchased approximately 1.5 million shares for $23.8 million in the quarter, ending with $551.5 million in cash and investments. The company also presented Phase 2 data for its drug candidate FID-007 at ASCO 2026. Fulgent Genetics operates as a technology-based genetic testing and therapeutic development company.